The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksHipgnosis Song. Regulatory News (SONG)

Share Price Information for Hipgnosis Song. (SONG)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 104.60
Bid: 104.60
Ask: 104.80
Change: -0.20 (-0.19%)
Spread: 0.20 (0.191%)
Open: 104.60
High: 105.20
Low: 104.40
Prev. Close: 104.80
SONG Live PriceLast checked at -
Hipgnosis Songs is an Investment Trust

To provide shareholders with an attractive and growing level of income, together with the potential for capital growth, from investment in songs and associated musical intellectual property rights.

Find out More

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Amendment to Operative Net Asset Value

18 Mar 2024 07:00

RNS Number : 1560H
Hipgnosis Songs Fund Limited
18 March 2024
 

LEI: 213800XJIPNDVKXMOC11

18 March 2024

Hipgnosis Songs Fund Limited ("Hipgnosis" or the "Company")

Amendment to Operative Net Asset Value

The Board of Hipgnosis Songs Fund is providing an amendment to its Operative Net Asset Value ("Operative NAV") following identification of an error due to the double counting of accrued revenue in the calculation of Operative NAV by Hipgnosis Song Management Limited (the "Investment Adviser"). This error results in a 7.6% reduction in the pro forma Operative NAV per Ordinary Share from $1.1657 (92.08 pence) as stated on 4 March 2024 to $1.0765 (85.03 pence).

 

The Board, as part of the strategic review, have been focused on the impact of Shot Tower's preliminary valuation, as announced on 4 March 2024. As part of this work the Board raised concerns with the Investment Adviser on the double counting of accrued revenue in the calculation of the Operative NAV, which results in an overstatement of the Operative NAV. This issue has been raised previously. The Investment Adviser has now notified the Board that they agree with the Board's view, contrary to previous advice.

 

Since flotation in July 2018, the Company has reported both an Operative NAV and an IFRS NAV for each accounting period. The Operative NAV is defined as the NAV as adjusted for the fair value of the Catalogues of Songs. The valuation methodology used by the Company's valuers assumes the transfer of rights to all future cash receipts including any income accrued at the date of sale. The Operative NAV should therefore deduct accrued income to avoid double counting. The error relates to the adjustment made to the IFRS NAV to produce the Operative NAV, which is prepared by the Investment Adviser, and does not relate to the valuation methodology used by the Company's valuer.

 

The impact of this double counting is a c.7.6% reduction of the Pro Forma Operative NAV as at 30 September 2023, using the midpoint NAV in Shot Tower's preliminary valuation report as announced on 4 March 2024, where the Pro-Forma Operative NAV would be $1.0765 per Ordinary Share (vs. $1.1657 per Ordinary Share) and 85.03 pence per Ordinary Share (vs. 92.08 pence per Ordinary Share) based on the Dollar to Sterling exchange rate of 1.266.

 

The equivalent impact using the Operative NAV disclosed in the Interim Results as at 30 September 2023 is a c. 5.1% reduction to $1.6500 per Ordinary Share (vs. $1.7392 per Ordinary Share) and to 135.19 pence per Ordinary Share (vs. 142.49 pence per Ordinary Share) based on the Dollar to Sterling exchange rate of 1.22055. The full change and amendments to the Operative NAV calculation are set out in the tables below.

 

 

30 September 2023 (as amended)

30 September 2023 (as presented)

 

$'000

$'000

IFRS NAV

1,331,529

1,331,529

Reverse Net Book Value of Catalogues of Songs

(1,850,447)

(1,850,447)

Reverse Accrued Income balance

(109,581)

Reverse Royalty Accruals on Accrued Income

1,754

-

Add fair value of Catalogues of Songs1

2,622,000

2,622,000

Operative NAV

1,995,255

 

2,103,082

No. shares in issue

1,209,214,286

1,209,214,286

Operative NAV per share ($)

1.6500

1.7392

Operative NAV per share (£)2

1.3519

1.4249

1Based on the valuation report for 30 September 2023 by Citrin Cooperman Advisors LLC

2Based on the Dollar to Sterling exchange rate of 1.22055 as at 30 September 2023

 

 

30 September 2023 (RNS as amended)

30 September 2023 (RNS)

 

$'000

$'000

IFRS NAV

1,331,529

1,331,529

Reverse Net Book Value of Catalogues of Songs

(1,850,447)

(1,850,447)

Reverse Accrued Income balance

(109,581)

Reverse Royalty Accruals on Accrued Income

1,754

-

Add fair value of Catalogues of Songs3,4

1,928,500

1,928,500

Pro Forma Operative NAV

1,301,755

1,409,582

 

No. shares in issue

1,209,214,286

1,209,214,286

Pro Forma Operative NAV per share ($)

1.0765

1.1657

Pro Forma Operative NAV per share (£)5

0.8503

0.9208

3 Based on the preliminary valuation report for 28 February 2024 prepared by Shot Tower Capital, LLC

4 Does not include c.20,000 songs sold post period end for $23.1 million, which had a fair value of $26.9m at 30 September 2023

5Based on the Dollar to Sterling exchange rate of 1.266 on 1 March 2024, being the last business day prior to the publication of the announcement of Shot Tower's preliminary valuation report

The Board has also sought confirmation from Shot Tower, who agrees that such adjustments previously made to produce the Operative NAV by the Investment Adviser are incorrect. None of the Company's banking covenants are impacted by the Operative NAV and therefore this amendment.

 

As the Operative NAV is a key valuation metric in defining the market capitalisation of the Company, the Company has almost certainly been overcharged investment advisory fees by the Investment Adviser. The Board has reserved all the Company's rights against the Investment Adviser.

 

For further information please contact:Hipgnosis Songs Fund

Robert Naylor

Via Singer Capital Markets

+44 (0) 20 7496 3000

 

 

Singer Capital Markets - Corporate Broker

James Moat / Alaina Wong / Angus Campbell (Corporate Finance)

Alan Geeves / James Waterlow / Sam Greatrex (Sales) 

+44 (0) 20 7496 3000

Headland Consultancy - Financial PR

Susanna Voyle / Charlie Twigg

 

+44 (0) 20 3805 4822

 

This announcement contains inside information for the purposes of the UK Market Abuse Regulation.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
MSCGPUQPWUPCPWM
Date   Source Headline
19th Apr 202410:38 amRNSForm 8.3 - Hipgnosis Songs Fund Limited
18th Apr 20243:40 pmRNSForm 8.3 - Hipgnosis Songs Fund Limited
18th Apr 20241:17 pmRNSForm 8.3 - Hipgnosis Songs Fund Limited
18th Apr 202411:14 amRNSForm 8.3 - Hipgnosis Songs Fund Limited
18th Apr 202410:26 amRNSForm 8.3 - Hipgnosis Songs Fund Limited
18th Apr 20247:00 amRNSRECOMMENDED CASH OFFER FOR HIPGNOSIS
15th Apr 20247:00 amRNSChange to Director roles and responsibilities
28th Mar 20249:02 amRNSFinal Due Diligence Findings
18th Mar 20247:00 amRNSAmendment to Operative Net Asset Value
4th Mar 20249:27 amRNSUpdate on Due Diligence, Valuation and NAV
4th Mar 20247:00 amRNSUpdate on Due Diligence, Valuation and NAV
26th Feb 20247:00 amRNSLitigation update
19th Feb 20247:00 amRNSLitigation Update
7th Feb 202412:35 pmRNSResult of Extraordinary General Meeting (“EGM”)
5th Feb 20247:00 amRNSLitigation Update
23rd Jan 20247:00 amRNSPublication of Circular/Update to Strategic Review
18th Jan 20247:00 amRNSProposed Change to Articles of the Company
11th Jan 20247:00 amRNSDirectorate Change
4th Jan 20243:26 pmRNSHolding(s) in Company
21st Dec 20237:00 amRNSInterim results to 30 September 2023
20th Dec 20237:00 amRNSChange of Auditor
19th Dec 20237:00 amRNSDelay to publication of interim results
15th Dec 20237:00 amRNSDirectorate Change
11th Dec 20237:00 amRNSAsset sale, adviser appointment, notice of results
28th Nov 202312:52 pmRNSHolding(s) in Company
23rd Nov 20237:00 amRNSStrategic Review and Company Update
20th Nov 20237:00 amRNSDirector/PDMR Shareholding
7th Nov 20237:00 amRNSDirectorate Changes
6th Nov 20237:00 amRNSUpdate on dividend intentions
26th Oct 202311:20 amRNSResult of AGM and EGM
25th Oct 20234:00 pmRNSDirectorate Changes, withdrawal of AGM Resolutions
24th Oct 20237:00 amRNSConclusion of Go-Shop process
19th Oct 20237:00 amRNSInitiation of Strategic Review, update on RCF
17th Oct 202312:22 pmRNSHolding(s) in Company
17th Oct 202312:21 pmRNSHolding(s) in Company
17th Oct 202312:18 pmRNSHolding(s) in Company
16th Oct 20236:17 pmRNSUpdate on CRB III and dividend payment
16th Oct 20237:13 amRNSUpdate on CRB III impact and dividend payment
28th Sep 202311:07 amRNSPublication of Circular and Notice of AGM & EGM
25th Sep 20232:41 pmRNSHolding(s) in Company
22nd Sep 202310:49 amRNSHolding(s) in Company
21st Sep 20237:00 amRNSDividend Declaration
20th Sep 20237:00 amRNSHolding(s) in Company
14th Sep 20237:00 amRNSAsset sales to fund buy backs and reduce debt
14th Aug 202312:29 pmRNSDirector/PDMR Shareholding
13th Jul 20237:00 amRNSAnnual Financial Report
10th Jul 20237:00 amRNSDirectorate Change and Notice of Results
23rd Jun 202312:02 pmRNSDividend Declaration
16th May 20237:00 amRNSCorrection of Director/PDMR Shareholding
15th May 20234:32 pmRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.